Australia markets closed

Eagle Pharmaceuticals, Inc. (EGRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
46.69+2.26 (+5.09%)
At close: 04:00PM EDT
47.00 +0.31 (+0.66%)
After hours: 05:28PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 569.81M
Enterprise value 527.92M
Trailing P/E 15.51
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.28
Price/book (mrq)2.64
Enterprise value/revenue 2.14
Enterprise value/EBITDA 9.24

Trading information

Stock price history

Beta (5Y monthly) 0.67
52-week change 33.37%
S&P500 52-week change 3-11.93%
52-week high 358.25
52-week low 341.01
50-day moving average 344.92
200-day moving average 348.83

Share statistics

Avg vol (3-month) 3137.18k
Avg vol (10-day) 3170.4k
Shares outstanding 513.21M
Implied shares outstanding 6N/A
Float 811.11M
% held by insiders 112.54%
% held by institutions 190.21%
Shares short (14 June 2022) 41.11M
Short ratio (14 June 2022) 48.01
Short % of float (14 June 2022) 416.65%
Short % of shares outstanding (14 June 2022) 48.71%
Shares short (prior month 12 May 2022) 4906.78k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 14.56%
Operating margin (ttm)26.96%

Management effectiveness

Return on assets (ttm)14.30%
Return on equity (ttm)17.62%

Income statement

Revenue (ttm)246.17M
Revenue per share (ttm)18.99
Quarterly revenue growth (yoy)180.90%
Gross profit (ttm)129.37M
Net income avi to common (ttm)35.85M
Diluted EPS (ttm)3.01
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)69.52M
Total cash per share (mrq)5.47
Total debt (mrq)27.62M
Total debt/equity (mrq)12.79
Current ratio (mrq)2.36
Book value per share (mrq)17.01

Cash flow statement

Operating cash flow (ttm)1.13M
Levered free cash flow (ttm)-5.07M